Case number# PHEH2015US009084, is an initial report received from a consumer (patient) on 07 May 2015 from a
patient oriented program: Gilenya Go Program (POP ID: POP00002581). This report refers to an adult female 
patient.
Medical history was not reported. No concomitant medication was reported. The patient received Gilenya 
(fingolimod) capsule (batch/lot number: S0090A (expiration date: Jun 2016) for the treatment of multiple sclerosis 
from 16 Mar 2015 at a dose of 0.5 mg, QD (oral). The patient stated that her blood work was showing up 
unfavorable, and there was no enough information as far as the PML. 
On an unknown date, the patient developed "JCV positive" (JC virus test positive). Action taken with Gilenya was 
treatment discontinued on 04 May 2015 (patient s HCP took her off Gilenya precautionary). 
The outcome of the event JC virus test positive was unknown. The seriousness assessment for JC virus test 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 450 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
positive was not reported by the consumer. Seriousness assessment of JC virus test positive was upgraded based 
on information available in the NVS-IME list. The causality of the event was not reported.